{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T19:15:27Z","timestamp":1788981327606,"version":"build-2803163510"},"reference-count":28,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2005,8,1]],"date-time":"2005-08-01T00:00:00Z","timestamp":1122854400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2005,8]]},"DOI":"10.1016\/j.ijantimicag.2005.04.011","type":"journal-article","created":{"date-parts":[[2005,6,14]],"date-time":"2005-06-14T11:25:42Z","timestamp":1118748342000},"page":"152-158","source":"Crossref","is-referenced-by-count":24,"title":["Significant increases in the levels of liver enzymes in mice treated with anti-tuberculosis drugs"],"prefix":"10.1016","volume":"26","author":[{"given":"Anne J.","family":"Lenaerts","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine M.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen S.","family":"Marrieta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Gruppo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian M.","family":"Orme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2005.04.011_bib1","doi-asserted-by":"crossref","first-page":"S221","DOI":"10.1164\/ajrccm.161.supplement_3.ats600","article-title":"Targeted tuberculin testing and treatment of latent tuberculosis infection","volume":"161","author":"American Thoracic Society","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ijantimicag.2005.04.011_bib2","first-page":"733","article-title":"Update: fatal and severe liver injuries associated with rifampin and pyrazinamide for latent tuberculosis infection, and revisions in American Thoracic Society\/CDC recommendations\u2014United States, 2001","volume":"50","author":"Centers for Disease Control and Prevention","year":"2001","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.ijantimicag.2005.04.011_bib3","first-page":"289","article-title":"Fatal and severe hepatitis associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection\u2014New York and Georgia, 2000","volume":"50","author":"Centers for Disease Control and Prevention","year":"2001","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.ijantimicag.2005.04.011_bib4","first-page":"735","article-title":"Update: adverse event data and revised American Thoracic Society\/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection\u2014United States, 2003","volume":"52","author":"Centers for Disease Control and Prevention","year":"2003","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.ijantimicag.2005.04.011_bib5","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1517\/13543784.12.8.1297","article-title":"Recent developments in the treatment of tuberculosis","volume":"12","author":"Davies","year":"2003","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.ijantimicag.2005.04.011_bib6","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/S0168-8278(97)80494-1","article-title":"Hepatotoxicity in drug development: detection, significance and solutions","volume":"26","author":"Ballet","year":"1997","journal-title":"J Hepatol"},{"key":"10.1016\/j.ijantimicag.2005.04.011_bib7","volume":"vol. 2","author":"Smith","year":"2002"},{"key":"10.1016\/j.ijantimicag.2005.04.011_bib8","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.1128\/AAC.40.12.2809","article-title":"Low-dose aerosol infection model for testing drugs for efficacy against Mycobacterium tuberculosis","volume":"40","author":"Kelly","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2005.04.011_bib9","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1128\/AAC.47.2.783-785.2003","article-title":"Rapid in vivo screening of experimental drugs for tuberculosis using gamma interferon gene-disrupted mice","volume":"47","author":"Lenaerts","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2005.04.011_bib10","unstructured":"WHO-ART Adverse Drug Reaction Terminology. WAADR. Geneva, Austria: WHO Collaborating Center for International Drug Monitoring; 1979."},{"key":"10.1016\/j.ijantimicag.2005.04.011_bib11","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1128\/AAC.43.5.1189","article-title":"Activities of several novel oxazolidinones against Mycobacterium tuberculosis in a murine model","volume":"43","author":"Cynamon","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2005.04.011_bib12","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1128\/AAC.42.8.2066","article-title":"In vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis","volume":"42","author":"Ji","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2005.04.011_bib13","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1128\/AAC.39.6.1341","article-title":"In vitro and in vivo activities of levofloxacin against Mycobacterium tuberculosis","volume":"39","author":"Ji","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2005.04.011_bib14","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1128\/AAC.38.10.2245","article-title":"Activity of KRM-1648, a new benzoxazinorifamycin, against Mycobacterium tuberculosis in a murine model","volume":"38","author":"Klemens","year":"1994","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2005.04.011_bib15","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1128\/AAC.38.7.1476","article-title":"Activity of levofloxacin in a murine model of tuberculosis","volume":"38","author":"Klemens","year":"1994","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2005.04.011_bib16","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/S0041-3879(63)80118-X","article-title":"Long-term, two-stage chemotherapy of advanced experimental murine tuberculosis with intermittent regimens during the second stage","volume":"44","author":"Canetti","year":"1963","journal-title":"Tubercle"},{"key":"10.1016\/j.ijantimicag.2005.04.011_bib17","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0041-3879(68)80016-9","article-title":"Suitability of isoniazid and ethambutol for intermittent administration in the treatment of tuberculosis","volume":"49","author":"Dickinson","year":"1968","journal-title":"Tubercle"},{"key":"10.1016\/j.ijantimicag.2005.04.011_bib18","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/0041-3879(70)90131-5","article-title":"Suitability of rifampicin for intermittent administration in the treatment of tuberculosis","volume":"51","author":"Dickinson","year":"1970","journal-title":"Tubercle"},{"key":"10.1016\/j.ijantimicag.2005.04.011_bib19","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/0041-3879(78)90007-7","article-title":"The sterilizing value of rifampicin and pyrazinamide in experimental short-course chemotherapy","volume":"59","author":"Grosset","year":"1978","journal-title":"Tubercle"},{"key":"10.1016\/j.ijantimicag.2005.04.011_bib20","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1128\/AAC.43.10.2356","article-title":"Evaluation of rifapentine in long-term treatment regimens for tuberculosis in mice","volume":"43","author":"Lenaerts","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2005.04.011_bib21","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1378\/chest.121.5.1710","article-title":"Death associated with rifampin and pyrazinamide 2-month treatment of latent Mycobacterium tuberculosis","volume":"121","author":"Medinger","year":"2002","journal-title":"Chest"},{"key":"10.1016\/j.ijantimicag.2005.04.011_bib22","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1378\/chest.123.1.102","article-title":"Pyrazinamide and rifampin vs. isoniazid for the treatment of latent tuberculosis","volume":"123","author":"McNeill","year":"2003","journal-title":"Chest"},{"key":"10.1016\/j.ijantimicag.2005.04.011_bib23","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1164\/rccm.200206-626OC","article-title":"Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis","volume":"167","author":"Yee","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ijantimicag.2005.04.011_bib24","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1056\/NEJM199404283301718","article-title":"Limited tolerance of ofloxacin and pyrazinamide prophylaxis against tuberculosis","volume":"330","author":"Horn","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2005.04.011_bib25","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1592\/phco.22.9.701.34065","article-title":"Limited tolerability of levofloxacin and pyrazinamide for multidrug-resistant tuberculosis prophylaxis in a solid organ transplant population","volume":"22","author":"Lou","year":"2002","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ijantimicag.2005.04.011_bib26","first-page":"131","article-title":"Adverse events associated with pyrazinamide and levofloxacin in the treatment of latent multidrug-resistant tuberculosis","volume":"167","author":"Papastavros","year":"2002","journal-title":"CMAJ"},{"key":"10.1016\/j.ijantimicag.2005.04.011_bib27","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1378\/chest.108.3.712","article-title":"Chemoprophylaxis of multidrug-resistant tuberculosis infection in HIV-uninfected individuals using ciprofloxacin and pyrazinamide. A decision analysis","volume":"108","author":"Stevens","year":"1995","journal-title":"Chest"},{"key":"10.1016\/j.ijantimicag.2005.04.011_bib28","first-page":"1265","article-title":"Asymptomatic hepatitis in persons who received alternative preventative therapy with pyrazinamide and ofloxacin","volume":"24","author":"Rizdon","year":"1997","journal-title":"Clin Infect Dis"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857905001391?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857905001391?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,2,25]],"date-time":"2019-02-25T06:57:24Z","timestamp":1551077844000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857905001391"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,8]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2005,8]]}},"alternative-id":["S0924857905001391"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2005.04.011","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2005,8]]}}}